Colorectal cancer needs better early detection and treatment options. Incidence is increasing in the young population. Circulating tumor DNA provides a way to select patients for adjuvant chemotherapy. Immunotherapy is an option for patients with mismatch repair protein deficiency. However, efficacy outside this patient population remains a challenge. Targeted therapies such as BRAF inhibitors are an option for poor prognosis patients for whom cytotoxic chemotherapy is not very effective.
• Managing Metastatic Disease
• Fecal occult blood test
• Recurrent Colon Cancer
• Flexible sigmoidoscopy
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
